Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

Kadia, TM; Reville, PK; Borthakur, G; Yilmaz, M; Kornblau, S; Alvarado, Y; Dinardo, CD; Daver, N; Jain, N; Pemmaraju, N; Short, N; Wang, SA; Tidwell, RSS; Islam, R; Konopleva, M; Garcia-Manero, G; Ravandi, F; Kantarjian, HM

Kadia, TM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.

LANCET HAEMATOLOGY, 2021; 8 (8): E552

Abstract

Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been shown to improve overall survival in older (aged 75 years or ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索